Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Related:

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer – New England Journal of Medicine

Commentary on Twitter:

In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding

8-year DMFI 97%
8-year BCSS 99.6%

Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE

— Paolo Tarantino (@PTarantinoMD) January 22, 2022